AXSM vs HSIC
Axsome Therapeutics, Inc. vs Henry Schein — AI-powered side-by-side comparison
AXSM
Axsome Therapeutics, Inc.
55
Watch
VS
| Metric | AXSM | HSIC |
|---|
| AI Score |
55
|
67
|
| Price |
$215.92
|
$89.16
|
| P/E Ratio |
-57.54×
|
25.77×
|
| ROE |
-207.5%
|
12.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
93.2%
|
30.3%
|
| Debt / Equity |
2.63×
|
1.21×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.5
|
59.4
|
| Beta |
0.596
|
0.808
|
| Expected Upside |
—
|
+0.8%
|
AI Committee View
Current Innellis committee reasoning for AXSM versus HSIC.
HSIC leads by 12 points.
HSIC scores 67/100 (Buy) versus AXSM at 55/100 (Watch).
AXSM Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 20.4% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 20.4% signals elevated volatility — Risk
HSIC Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth